Karin Rexroad peeks through the bore of the PET-CT scanner at LMH Health. Positron emission tomography, or PET, scans have long been used to diagnose cancer and determine how far it has progressed.

The U.S. Food and Drug Administration (FDA) has approved flurpiridaz F-18 (Flyrcado; GE Healthcare), a first-of-its-kind positron emission tomography (PET) imaging agent, for use in adult patients ...

Figure 1. Exercise/rest measurements of the standardized uptake value ratio (SUVR) are used with an exponential calibration function to estimate myocardial flow reserve (MFR). This allows (i) the ...

GE HealthCare has secured the FDA’s approval for an injectable, radioactive imaging agent that gives clinicians a clearer picture into blocked arteries in the heart and any damage to cardiac tissue.

GE HealthCare GEHC recently unveiled new advancements in precision cardiac care at the 2025 SNMMI annual meeting in New Orleans, with a spotlight on Flyrcado—its FDA-approved Positron Emission ...

Patients in East Texas now have access to a new, advanced form of heart-imaging technology that physicians say can provide clearer, more accurate evaluations of blood flow to the heart and help detect ...

GE HealthCare’s FDA-approved flurpiridaz F 18 PET radiotracer, Flyrcado, delivers higher diagnostic efficacy in patients with known or suspected coronary artery disease (CAD), compared to SPECT MPI, ...

A new radioactive tracer for positron emission tomography (PET) myocardial perfusion imaging will soon be available in the United States, and it’s expected to facilitate substantial growth in such ...

The National Heart Center Singapore (NHCS) announces a major advancement in cardiac care research with the implementation of SENSE (Singapore hEart lesioN analySEr), a nationwide AI initiative that ...